Vol 18, No 3 (2016)


Who or what does influence the optimal choice of medication administration route? Is this the solution of clinician, patient or State? New and it should seem unexpected questions for Russian Health Care

Kolbin A.S., Gomon Y.M., Khokhlova S.V.


New treatment options of chronic diseases, concerning the different selection of therapy regimens, as well as the system of drug administration (outpatiently, domiciliary, at hospital) started up over the last decade. The patient's awareness of the availability of treatment alternatives is an important benefit factor in terms of adherence of patients to treatment and preserving quality of life. The aim of this study was to examine the factors influencing the choice of medication administration route, used in case of various nosologies. In view of this we analyzed all publications in the PubMed database in the period of 1990 to 2016, concerning the comparison of efficacy, safety, pharmacoeconomic, patient preferences, in case of different medication administration route. As a result of the database analysis we incontestably proved that the basic criteria of medication selection were efficiency, safety, pharmacoeconomic aspects and patient preference. Patient preference is an important factor in achieving high adherence to treatment, increasing the efficiency of medical technology and enhancing quality of life.
Journal of Modern Oncology. 2016;18(3):12-18
pages 12-18 views

The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation in 2015

Poddubnaya I.V., Frank G.A., Yagudina R.I., Koroleva N.I., Zavalishina L.E.


Since 2006 the epidemiological HER2 screening program in patients with breast cancer was started in all federal regions of Russia. The main aims of this program were implementation HER2 diagnostic in routine practice and improvement diagnostic on regional level. The data received in frame of execution of this program is important additional information that used for analysis of annually published journal "State of Oncology Aid Rendered to Population of Russia". This article presents results of HER2 screening epidemiological program in 2015 and provides comparative data analysis since 2012 to 2016 years.
Journal of Modern Oncology. 2016;18(3):19-26
pages 19-26 views

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia

Bolotina L.V., Manziuk L.V., Gorbunova V.A., Kovalenko E.I., Mukhametshina G.Z., Khasanova A.I., Vladimirova L.Y., Mitashok I.S., Prokofyeva E.P., Evstigneeva I.V., Andreyashkina I.I., Abramova N.A., Popova I.L., Karabina E.V., Teterich A.A., Gaysina E.A., Chubenko V.A., Limareva S.V., Tikhanovskaya N.M., Storozhakova A.E., Samaneva N.Y., Svetitskaya Y.V., Snezhko T.A., Kalabanova E.A.


The article shows the experience of eribulin application in actual clinical practice in Oncology institutions of the Russian Federation concerning metastatic breast cancer. We have analyzed the efficacy of the drug in case of different subtypes of the tumor and have chosen patients, depending on the location of metastases and with proven maximum efficacy of eribulin. We have shown the side reactions and the possibility of application of eribulin in combination with other antineoplastic agents.
Journal of Modern Oncology. 2016;18(3):27-32
pages 27-32 views

The role of nab-paclitaxel in the treatment of patients with metastatic breast cancer

Frolova M.A.


Nab-paclitaxel is nanoparticle albumin-bound paclitaxel. Nab-paclitaxel is free from any kind of solvent and thus reduces the risk of hypersensitivity reactions and other side effects, compared with standard taxanes (paclitaxel, docetaxel). There is no need to use premedication with glucocorticoids and antihistamines during nab-paclitaxel application. In addition, several studies have demonstrated that nab-paclitaxel allows achieving a higher drug concentration in tumor. The article deals with the basic studies of nab-paclitaxel application using different doses and introduction regimens in patients with metastatic breast cancer. We show the algorithm for optimal use of nab-paclitaxel in different clinical cases.
Journal of Modern Oncology. 2016;18(3):33-37
pages 33-37 views

Neuroendocrine tumors of the colon: an analysis of the literature and own experience

Kochatkov A.V., Bogomazova S.Y., Negardinov A.Z., Alimova Y.V., Lyadov V.K.


Neuroendocrine tumors (NET) of the colon and rectum are rare diseases. In the treatment of patients with these rare diseases one should follow special standards which are differed from the standards of adenocarcinoma treatment. This article has analyzed the modern national literature, as well as our own experience in the treatment of 9 patients with NET of the colon in the period of 2007 to 2015. Average age - 60±14.6 years. Only NET of the rectum was identified at the first stage of the cancer. Endoscopic surgery was performed in 3 patients: two patients underwent endoscopic removal of the tumor and one - transanal endoscopic microsurgery associated with full-thickness resection of the rectum. Right-sided hemicolectomy was performed in 3 patients and anterior resection of the rectum (ARR) - in 1 patient. All operations were performed using standard oncology protocol associated with D2 lymph node dissection. We estimated the long-term outcomes of patients’ treatment. We analyzed the proposed by European colleagues algorithm of the treatment tactics in patients with neuroendocrine tumors of the colon, which in our point of view could be useful in medical practice of Russian doctors.
Journal of Modern Oncology. 2016;18(3):38-42
pages 38-42 views

Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice

Sekacheva M.I., Bagmet N.N.


The problem of the treatment of metastatic colorectal cancer makes us to continue for seeking new ways of severe disease treatment. Regorafenib is the newest drug for use in patients who have received all possible variants of therapy. The efficacy and safety of regorafenib are proved by the results of randomized clinical trials. While in Russia the drug has only recently entered the market, but in the world scientists have already accumulated the wide experience of regorafenib application in actual clinical practice, that allows developing special approaches to selection and management of patients, achieving maximum results. This article showes the results of the review concerning foreign and Russian experience of the drug application.
Journal of Modern Oncology. 2016;18(3):43-47
pages 43-47 views

Modern therapy of radioactive iodine-refractory differentiated thyroid cancer: resolution of the Expert Council

Rumyantsev P.O., Gorbunova V.A., Podvyaznikov S.O., Zhukov N.V., Isaev P.A., Krylov V.V., Mudunov A.M., Rodichev A.A., Shavarova E.K.


The meeting of experts, concerning the treatment of thyroid cancer was held in Moscow in June 2016. The aim of the meeting was unsolved tasks in the field of therapy of the patients with radioactive iodine-refractory differentiated thyroid cancer. Nowadays, this group of patients still has a poor prognosis with respect to life expectancy. The experts are faced with some difficulties in choosing the treatment tactics in patients after radioiodine therapy have become ineffective and we observe disease progression. And still valid questions remain unsolved: when should doctors stop therapy using radioactive iodine? When should patient start therapy using targeted agents? What kind of targeted agent should specialist choose for treatment of this desiase? How should one manage the developing side effects against the backdrop of targeted therapy? These and some other problems have been discussed within the framework of this counsel.
Journal of Modern Oncology. 2016;18(3):48-51
pages 48-51 views

Liposarcomas: morphological subtypes, prognostic factors and therapeutic options

Fedenko A.A.


The article shows the literature review of the biology, prognostic factors and the results of liposarcomas treatment according to the histological subtypes and the localization of the primary tumor. We are also discussing the modern options of systemic therapy, including the original chemotherapy regimens, developed in N.N.Blokhin Russian Cancer Research Center, and new effective therapeutic agents.
Journal of Modern Oncology. 2016;18(3):52-58
pages 52-58 views

Therapy results of advanced-stag Hodgkin lymphoma in Khabarovsk district

Kanin V.S., Kanin E.S., Dolgaleva M.I.


Objectives. To evaluate therapy results of advanced-stag Hodgkin lymphoma (HL) in Kraev Oncology Centre, Khabarovsk district. Methods. The study included 76 patients with Hodgkin's lymphoma. They were observed in the Regional Oncology Centre in Khabarovsk district in the period from May 2007 to May 2015. The median age was 31 (range from 18 to 61 years of age). Patients received modified BEACOPP regimen therapy. Results. According to therapy results of advanced-stag HL at the median of 53 months, the median of overall survival and disease-free survival was not reached. The rates of survival were 89.1 and 94.9% respectively, and the failure free survival was 86.6%. Using of the modified BEACOPP protocol therapy was accompanied by predictable and avoidable side effects. The hematological toxicity of 3-4 degree of development of leukopenia was observed in 74.5% of cases; anemia and thrombocytopenia in 16.5 and 14.9% respectively. Conclusions. The modified BEACOPP protocol is highly effective in the treatment of Hodgkin’s lymphoma and leads to significant improvement in overall survival.
Journal of Modern Oncology. 2016;18(3):59-64
pages 59-64 views

Experience in prevention of neutropenia in patients with disseminated soft tissue sarcomas receiving polychemotherapy

Vladimirova L.Y., Mitashok I.S., Snezhko T.A., Samaneva N.Y., Storozhakova A.E., Kornilova I.S.


The main treatment for metastatic soft tissue sarcomas is chemotherapy (CT); neutropenia is its frequent complication that is treated with various colony stimulating factors (CSFs). The purpose of the study was to assess the treatment effectiveness and frequency of adverse events in administration of various CSFs (filgrastim, pegfilgrastim and lipegfilgrastim) in patients with disseminated soft tissue sarcomas receiving myelosuppressive CT. Data on 34 patients firstly diagnosed with disseminated soft tissue sarcomas were studied; the patients received 4 cycles of CT: doxorubicin plus ifosfamide, combined with CSFs: filgrastim daily or a single injection of long-acting CSFs. Following results were received: both duration and severity of neutropenia were highest in the filgrastim group. Frequency of febrile neutropenia requiring antibacterial treatment and the number of cases of discontinuation of cytostatics or dose reduction associated with hematological complications during the cycles 1-4 were significantly lower in patients receiving pegfilgrastim and lipegfilgrastim. Musculoskeletal pain was the most frequent adverse event during cytokine administration. Thus, a single injection of pegfilgrastim and lipegfilgrastim contributed to a significant reduction of neutropenia duration and severity, compared with daily filgrastim, with similar safety profiles of the drugs.
Journal of Modern Oncology. 2016;18(3):65-68
pages 65-68 views

Tracheal and bronchial plastic resection in patients with lung cancer

Khvastunov R.A., Usachev A.A.


This article presents our experience of bronhoplastic operations. In the structure: 11 - pneumonectomy with resection of the bifurcation of the trachea, 61 lobectomy and bilobectomy, including 13 angioplastic operations. There were not postoperative complications and mortality in our research. The article discussed the indications and technique of performing of operations.
Journal of Modern Oncology. 2016;18(3):69-75
pages 69-75 views

Circulating tumor cell: biology, methods of isolation, clinical significance in breast cancer

Nenahova Y.N., Lyadov V.K., Poddubnaya I.V.


Breast cancer is the most common female oncopathology in the world. The main cause of mortality in patients - metastases. The current state of medicine allows curing the primary tumor, but often is not effective enough to control the development of metastatic disease. Of great importance in the implementation of metastatic cascade plays circulation and survival of tumor cells in the peripheral blood. In this article we have tried to summarize and present the data in the literature on the study of circulating tumor cells in patients with breast cancer.
Journal of Modern Oncology. 2016;18(3):76-83
pages 76-83 views

Clinico-economic evaluation of different treatment strategies in patients with non-small cell lung cancer and mutations in the EGFR gene

Ryazhenov V.V., Gorokhova S.G.


The article presents the results of pharmacoeconomic study concerning different approaches to treat patients with non-small cell lung cancer and mutations in the EGFR gene. We have compared two common therapy regimens, which are used in routine practice in this group of patients, nowadays: the standard chemotherapy - carboplatin/paclitaxel combination and targeted therapy, using gefitinib. The results of the study demonstrate the clinical and economic benefits of gefitinib, proved by preferable cost-effectiveness ratio and reduced financial costs taking into account the effective treatment ratio patients/months.
Journal of Modern Oncology. 2016;18(3):84-89
pages 84-89 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies